RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, presented results of a multi-institutional prospective study from 492 patient outcomes on integrated molecular pathology (IMP) at the recently held 2013 ACG Annual Meeting in San Diego, CA. Final data results validate the company’s PathFinderTG® pancreas platform’s high negative predictive value (NPV=97%) for correctly identifying patients at very low risk of developing pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
